Suppr超能文献

男性肾性尿崩症患者对 1-脱氨基-8-右旋精氨酸血管加压素(去氨加压素)无反应:从实验室到临床。

Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside.

机构信息

Internal Medicine, CHU Erasme, Université Libre de Bruxelles 808, Route de Lennik 1080 Brussels, Belgium.

出版信息

Eur J Clin Invest. 2012 Mar;42(3):254-9. doi: 10.1111/j.1365-2362.2011.02576.x. Epub 2011 Aug 11.

Abstract

BACKGROUND

Nephrogenic syndrome of inappropriate antidiuresis (NSIAD) is a recently described entity, linked to gain-of-function mutations (R137C and R137L) in arginine vasopressin (AVP) gene leading to chronic activation of tubular V2 AVP receptor (V2R) and thus free water reabsorption. In addition to collecting duct cells, the V2R is also expressed in endothelial cells, where it mediates the rise in circulating levels of von Willebrand factor (vWF) and coagulation factor VIII (fVIII). Recent in vitro data showed that these mutant receptors are resistant to vasopressin-stimulated cAMP production. We aimed to explore by clinical observations the sensitivity to vasopressin of the R137C-V2R mutant in vivo.

MATERIAL AND METHODS

We performed a stimulation test with 1-desamino-D arginin vasopressin (dDAVP) 0·3 μg/kg of bodyweight in three patients (two hemizygous male and one heterozygous female) with NSIAD with R137C mutation and measured on the one hand the levels of vWF and fVIII and the other hand urine osmolality and albumin excretion (UAE).

RESULTS

Whereas the female heterozygous patient displayed normal response to simulation by dDAVP (except for UAE), no increase in vWF, fVIII, urinary osmolality and UAE was observed among hemizygous male patients.

CONCLUSIONS

Coherent with in vitro observation in transfected cells, our clinical observations demonstrate that the R137C-V2R mutant is resistant to vasopressin stimulation in its physiological sites of expression.

摘要

背景

肾源性尿崩症(NSIAD)是一种新近描述的病症,与精氨酸加压素(AVP)基因中的功能获得性突变(R137C 和 R137L)有关,这些突变导致肾小管 V2 加压素受体(V2R)持续激活,从而导致自由水重吸收。除了集合管细胞外,V2R 也在血管内皮细胞中表达,在那里它介导血管性血友病因子(vWF)和凝血因子 VIII(fVIII)的循环水平升高。最近的体外数据表明,这些突变受体对加压素刺激的 cAMP 产生具有抗性。我们旨在通过临床观察探索体内 R137C-V2R 突变体对加压素的敏感性。

材料和方法

我们对 3 名患有 R137C 突变的 NSIAD 患者(2 名半合子男性和 1 名杂合子女性)进行了 1-脱氨基-D-精氨酸加压素(dDAVP)0.3 μg/kg 体重的刺激试验,并测量了 vWF 和 fVIII 的水平,另一方面测量了尿渗透压和白蛋白排泄率(UAE)。

结果

尽管杂合子女性患者对 dDAVP 的模拟反应正常(除了 UAE 之外),但半合子男性患者中未观察到 vWF、fVIII、尿渗透压和 UAE 的增加。

结论

与转染细胞的体外观察一致,我们的临床观察表明,R137C-V2R 突变体在其生理表达部位对加压素刺激具有抗性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验